



NATIONAL MEDICAL SERVICES

January 31, 2006

Dear Valued Client:

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled the enclosed packet of important changes regarding a number of tests we perform. Listed below are the types of changes included in this packet.

Category	Type of Change
I.	Tests that have had changes to their method/CPT code, units of measurement, scope of analysis or specimen requirements
II.	Tests that have been discontinued
III.	Tests that have had reference comment changes

Please be advised that the changes listed in this packet will go into effect on **May 1, 2006**. Please use this packet of information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

We apologize if this causes you any inconvenience. If you have any questions about the information contained in this packet, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of National Medical Services and your assistance in implementing these changes.

Sincerely,

National Medical Services, Inc.

Database Changes - Summary

Categories:

- I: Method/CPT Code, Units, Scope of Analysis and Specimen Requirements
- II: Deleted tests
- III: Reference comment changes

Test Code	Test Name	Category		
		I	II	III
0410U	Antimony, Urine	•		
0460U	Arsenic, Urine	•		
0465U	Arsenic Biouptake Survey, Urine	•		
0468U	Arsenic, Total Inorganic, Urine	•		
0711B	Boron, Blood			•
0711SP	Boron, Serum/Plasma			•
0802B	Buprenorphine and Metabolite Screen - Free (Unconjugated), Blood	•		
0802R	Buprenorphine and Metabolite Screen - Free (Unconjugated), RBCs	•		
0802SP	Buprenorphine and Metabolite Screen - Free (Unconjugated), Serum/Plasma	•		
0802U	Buprenorphine and Metabolite Screen - Total (Conjugated/Unconjugated), Urine	•		
0921U	Cadmium Biouptake, Urine	•		
1261U	Chromium, Urine	•		
1810B	Doxepin and Metabolite, Blood			•
1810SP	Doxepin and Metabolite, Serum/Plasma			•
2105B	Fluoxetine and Metabolite, Blood			•
2105SP	Fluoxetine and Metabolite, Serum/Plasma			•
2110B	Fluphenazine, Blood			•
2110SP	Fluphenazine, Serum/Plasma			•
2427B	Inhalants Survey (Comprehensive), Blood	•		•
2427U	Inhalants Survey (Comprehensive), Urine	•		
2492U	Lead, Urine	•		
2662U	Metals/Metalloids Panel 2, Urine	•		
2663U	Metals/Metalloids Panel 3, Urine	•		
2670U	Mercury, Urine	•		
2675U	Mercury Exposure Survey, Urine	•		
3036U	Methyltin, Urine	•		
3037U	Butyl-Tins, Urine	•		
3110B	Nalbuphine Screen - Free (Unconjugated), Blood	•		•
3110SP	Nalbuphine Screen - Free (Unconjugated), Serum/Plasma	•		•
3110U	Nalbuphine Screen - Total (Conjugated/Unconjugated), Urine	•		
3140U	Nickel, Urine	•		
3656B	Phenothiazines Panel, Blood			•
3656SP	Phenothiazines Panel, Serum/Plasma			•
3960B	Promazine, Blood			•
3960SP	Promazine, Serum/Plasma			•
3778U	Plutonium, Urine		•	
4082U	Radioisotope Panel, Urine		•	
4084U	Radium, Urine		•	
4240U	Sufentanil, Urine	•		
4551U	Tritium, Urine		•	
4472U	Thiosulfate, Urine	•		
4627U	Trichloroacetic Acid, Urine	•		
4649U	Trichloroethylene Exposure Survey, Urine	•		
4655B	Antidepressants Panel 1, Blood			•
4655SP	Antidepressants Panel 1, Serum/Plasma			•
4778U	Vinyl Chloride Metabolite, Urine	•		

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Categories:

- I: Method/CPT Code, Units, Scope of Analysis and Specimen Requirements
- II: Deleted tests
- III: Reference comment changes

Test Code	Test Name	Category		
		I	II	III
4817U	Whitford Survey, Urine	•		
4821U	Xylene Exposure Panel, Urine	•		
5113B	Buprenorphine and Metabolite Confirmation - Free (Unconjugated), Blood	•		
5113R	Buprenorphine and Metabolite Confirmation - Free (Unconjugated), RBCs	•		
5113SP	Buprenorphine and Metabolite Confirmation - Free (Unconjugated), Serum/Plasma	•		
5113U	Buprenorphine and Metabolite Confirmation - Total (Conjugated/Unconjugated), Urine	•		
5118B	Nalbuphine Confirmation - Free (Unconjugated), Blood	•		•
5118SP	Nalbuphine Confirmation - Free (Unconjugated), Serum/Plasma	•		•
5118U	Nalbuphine Confirmation - Total (Conjugated/Unconjugated), Urine	•		
5222B	Antidepressants Quantitation/Confirmation, Blood (Forensic)			•
5222SP	Antidepressants Quantitation/Confirmation, Serum/Plasma (Forensic)			•
5450B	Antidepressants Confirmation, Blood			•
5450SP	Antidepressants Confirmation, Serum/Plasma			•
5545SP	Phenothiazines Confirmation, Serum/Plasma			•
5684U	Benzphetamine and Metabolite Confirmation, Urine			•
5781U	Alfentanil Confirmation, Urine	•		
5782U	Sufentanil Confirmation, Urine	•		
6100LI	Dialysis Water Analysis	•		
6303U	Firefighter Core Baseline Survey, Urine	•		
8121B	Common Drugs of Abuse Screen, Blood (Forensic)		•	
8121SP	Common Drugs of Abuse Screen, Serum/Plasma (Forensic)		•	
8121U	Common Drugs of Abuse Screen, Urine (Forensic)		•	
8400U	Drugs of Abuse - Medical Professionals, Urine (Forensic)	•		
8600U	Amphetamines Panel, Urine			•
8676U	Opiates - Total (Conjugated and Unconjugated), Urine		•	
8680B	Phenothiazines Panel, Blood			•
8680SP	Phenothiazines Panel, Serum/Plasma			•
8686B	Promazine, Blood			•
8686SP	Promazine, Serum/Plasma			•
8700B	Antidepressants Panel, Blood			•
8700SP	Antidepressants Panel, Serum/Plasma			•
9400U	Drugs of Abuse - Medical Professionals, Urine (Forensic)	•		
9420SP	Phenothiazines Screen, Serum/Plasma			•
9431B	Antidepressants Screen, Blood			•
9431SP	Antidepressants Screen, Serum/Plasma			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
5781U	Alfentanil Confirmation, Urine Scope of Analysis: Alfentanil, N-Desalkylalfentanil N-Desalkylalfentanil [ng/mL; LC/MS/MS] was added.		
0410U	Antimony, Urine Scope of Analysis: Creatinine, Antimony, Antimony (Creatinine corrected) Antimony (Creatinine correction) was removed. Antimony (Creatinine corrected) [mcg/g Creat; ICP/MS] was added		
0465U	Arsenic Biouptake Survey, Urine Scope of Analysis: Creatinine, Arsenic, Arsenic (Creatinine corrected), Arsenic, Total Inorganic, Arsenic, Total Inorganic (Creatinine corrected) Arsenic (Creatinine correction) and Arsenic, Total Inorganic (Creatinine correction) were removed. Arsenic (Creatinine corrected) [mcg/g Creat; ICP/MS] and Arsenic, Total Inorganic (Creatinine corrected) [mcg/g Creat; ICP/MS] were added. Order of reported analytes was changed.		
0468U	Arsenic, Total Inorganic, Urine Scope of Analysis: Creatinine, Arsenic, Total Inorganic, Arsenic, Total Inorganic (Creatinine corrected) Arsenic, Total Inorganic (Creatinine correction) was removed. Arsenic, Total Inorganic (Creatinine corrected) [mcg/g Creat; ICP/MS] was added Specimen Requirements: 5 mL end of shift at end of work week Urine Collection Notes: Collect sample at end of shift at end of work week in a trace metal free or acid washed plastic container. Required volume was changed.		
0460U	Arsenic, Urine Scope of Analysis: Creatinine, Arsenic, Arsenic (Creatinine corrected) Arsenic (Creatinine correction) was removed. Arsenic (Creatinine corrected) [mcg/g Creat; ICP/MS] was added		
0802B	Buprenorphine and Metabolite Screen - Free (Unconjugated), Blood Scope of Analysis: Buprenorphine - Free, Norbuprenorphine - Free Buprenorphine and Norbuprenorphine were removed. Buprenorphine - Free [ng/mL; LC/MS/MS] and Norbuprenorphine - Free [ng/mL; LC/MS/MS] were added. Test Name was changed.		
0802R	Buprenorphine and Metabolite Screen - Free (Unconjugated), RBCs Scope of Analysis: Buprenorphine - Free, Norbuprenorphine - Free Buprenorphine and Norbuprenorphine were removed. Buprenorphine - Free [ng/mL; LC/MS/MS] and Norbuprenorphine - Free [ng/mL; LC/MS/MS] were added. Test Name was changed.		
0802SP	Buprenorphine and Metabolite Screen - Free (Unconjugated), Serum/Plasma Scope of Analysis: Buprenorphine - Free, Norbuprenorphine - Free Buprenorphine and Norbuprenorphine were removed. Buprenorphine - Free [ng/mL; LC/MS/MS] and Norbuprenorphine - Free [ng/mL; LC/MS/MS] were added. Test Name was changed.		

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
0802U	Buprenorphine and Metabolite Screen - Total (Conjugated/Unconjugated), Urine		
Scope of Analysis: Buprenorphine - Total, Norbuprenorphine - Total Buprenorphine and Norbuprenorphine were removed. Buprenorphine - Total [ng/mL; LC/MS/MS] and Norbuprenorphine - Total [ng/mL; LC/MS/MS were added. Test Name was changed.			
5113B	Buprenorphine and Metabolite Confirmation - Free (Unconjugated), Blood		
Scope of Analysis: Buprenorphine- Free, Norbuprenorphine- Free Buprenorphine and Norbuprenorphine were removed. Buprenorphine – Free [ng/mL; LC/MS/MS] and Norbuprenorphine - Free [ng/mL; LC/MS/MS] were added. Test Name was changed.			
5113R	Buprenorphine and Metabolite Confirmation - Free (Unconjugated), RBCs		
Scope of Analysis: Buprenorphine - Free, Norbuprenorphine - Free Buprenorphine and Norbuprenorphine were removed. Buprenorphine - Free [ng/mL; LC/MS/MS] and Norbuprenorphine – Free [ng/mL; LC/MS/MS] were added. Test Name was changed.			
5113SP	Buprenorphine and Metabolite Confirmation - Free (Unconjugated), Serum/Plasma		
Scope of Analysis: Buprenorphine- Free, Norbuprenorphine- Free Buprenorphine and Norbuprenorphine were removed. Buprenorphine – Free [ng/mL; LC/MS/MS] and Norbuprenorphine – Free [ng/mL; LC/MS/MS] were added. Test Name was changed.			
5113U	Buprenorphine and Metabolite Confirmation - Total (Conjugated/Unconjugated), Urine		
Scope of Analysis: Buprenorphine - Total, Norbuprenorphine - Total Buprenorphine and Norbuprenorphine were removed. Buprenorphine - Total [ng/mL; LC/MS/MS] and Norbuprenorphine - Total [ng/mL; LC/MS/MS] were added. Test Name was changed.			
3037U	Butyl-Tins, Urine		
Scope of Analysis: Creatinine, Monobutyltin, Monobutyltin (Creatinine corrected), Dibutyltin, Dibutyltin (Creatinine corrected), Tributyltin, Tributyltin (Creatinine corrected) Mono-Butyltin, Mono-Butyltin (Creatinine correction), Di-Butyltin, Di-Butyltin (Creatinine correction), Tri-Methyltin and Tri-Methyltin (Creatinine correction) were removed. Monobutyltin [ng/mL; GC], Monobutyltin (Creatinine corrected) [mcg/g Creat; GC], Dibutyltin [ng/mL; GC], Dibutyltin (Creatinine corrected) [mcg/g Creat; GC], Tributyltin [ng/mL; GC] and Tributyltin (Creatinine corrected) [mcg/g Creat; GC] were added.			
0921U	Cadmium Biouptake, Urine		
Scope of Analysis: Creatinine, Cadmium, Cadmium (Creatinine corrected) Cadmium (Creatinine correction) was removed. Cadmium (Creatinine corrected) [mcg/g Creat; ICP/MS] was added. Order of reported analytes was changed.			
1261U	Chromium, Urine		
Scope of Analysis: Creatinine, Chromium, Chromium (Creatinine corrected) Chromium (Creatinine correction) was removed. Chromium (Creatinine corrected) [mcg/g Creat; GFAAS] was added. Order of reported analytes was changed.			

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
6100LI Dialysis Water Analysis Specimen Requirements: 40 mL Liquid Notes: Protection from light is required. Failure to submit a light protected sample will result in cancellation. Required volume was changed.			
8400U Drugs of Abuse - Medical Professionals, Urine (Forensic) Scope of Analysis: Benzodiazepines, Opiates, Cocaine/Metabolites, Desalkylflurazepam, Nordiazepam, Oxazepam, Lorazepam, Diazepam, Hydroxyethylflurazepam, Temazepam, Chlordiazepoxide, Midazolam, Flurazepam, Alpha-Hydroxyalprazolam, Alprazolam, Hydroxytriazolam, Triazolam, Estazolam, Ketamine, Meperidine, Pentazocine, Morphine - Total, Hydromorphone - Total, Naltrexone - Total, Buprenorphine - Total, Norbuprenorphine - Total, Butorphanol - Total, Nalbuphine - Total, Naloxone - Total, Fentanyl, Sufentanil, N-Desalkylsufentanil, Alfentanil, N-Desalkylalfentanil, Norfentanyl N-Desalkylsufentanil [ng/mL; LC/MS/MS] and N-Desalkylalfentanil [ng/mL; LC/MS/MS] were added.			
9400U Drugs of Abuse - Medical Professionals, Urine (Forensic) Scope of Analysis: Opiates, Cocaine/Metabolites, Cannabinoids, Desalkylflurazepam, Nordiazepam, Oxazepam, Lorazepam, Diazepam, Hydroxyethylflurazepam, Temazepam, Chlordiazepoxide, Midazolam, Flurazepam, Alpha-Hydroxyalprazolam, Alprazolam, Hydroxytriazolam, Triazolam, Estazolam, Ketamine, Meperidine, Pentazocine, Morphine - Total, Hydromorphone - Total, Naltrexone - Total, Buprenorphine - Total, Norbuprenorphine - Total, Butorphanol - Total, Nalbuphine - Total, Naloxone - Total, Fentanyl, Sufentanil, N-Desalkylsufentanil, Alfentanil, N-Desalkylalfentanil, Norfentanyl N-Desalkylsufentanil [ng/mL; LC/MS/MS] and N-Desalkylalfentanil [ng/mL; LC/MS/MS] were added.			
6303U Firefighter Core Baseline Survey, Urine Scope of Analysis: Creatinine, Cadmium, Cadmium (Creatinine corrected), Antimony, Antimony (Creatinine corrected), Mercury, Mercury (Creatinine corrected) Cadmium (Creatinine correction), Antimony (Creatinine correction) and Mercury (Creatinine correction) were removed Cadmium (Creatinine corrected) [mcg/g Creat; ICP/MS], Antimony (Creatinine corrected) [mcg/g Creat; ICP/MS] and Mercury (Creatinine corrected) [mcg/g Creat; CVAAS] were added.			
2427B Inhalants Survey (Comprehensive), Blood Volatiles Hydrocarbon Gases Halocarbons Hydrocarbon Gase s units were changed			ppm (v/v)
2427U Inhalants Survey (Comprehensive), Urine Scope of Analysis: Phenol - Total, o-Cresol, Acetone, Ethanol, Isopropanol, Methanol, Methyl Ethyl Ketone, Methyl Isobutyl Ketone, Hippuric Acid, Methylhippuric Acid, Mandelic Acid, Phenylglyoxylic Acid, Trichloro-organic Metabolites Trichlororganic Metabolites was removed. Trichloro-organic Metabolites [mg/L; SP] was added.			

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
2492U	Lead, Urine Scope of Analysis: Creatinine, Lead, Lead (Creatinine corrected), Antimony, Antimony (Creatinine corrected), Mercury, Mercury (Creatinine corrected) Lead (Creatinine correction) was removed Lead (Creatinine corrected) [mcg/g Creat; ICP/MS] was added.		
2670U	Mercury, Urine Scope of Analysis: Creatinine, Mercury, Mercury (Creatinine corrected) Mercury (Creatinine correction) was removed Mercury (Creatinine corrected) [mcg/g Creat; CVAAS] was added.		
2675U	Mercury Exposure Survey, Urine Scope of Analysis: Creatinine, Mercury, Mercury (Creatinine corrected) Mercury (Creatinine correction) was removed Mercury (Creatinine corrected) [mcg/g Creat; CVAAS] was added.		
2662U	Metals/Metalloids Panel 2, Urine Scope of Analysis: Creatinine, Thallium, Thallium (Creatinine corrected), Cadmium, Cadmium (Creatinine corrected) Manganese, Manganese (Creatinine corrected), Nickel, Nickel (Creatinine corrected) Thallium (Creatinine correction), Cadmium (Creatinine correction), Manganese (Creatinine correction) and Nickel (Creatinine correction) were removed Thallium (Creatinine corrected) [mcg/g Creat; ICP/MS], Cadmium (Creatinine corrected) [mcg/g Creat; ICP/MS], Manganese (Creatinine corrected) [mcg/g Creat; ICP/MS] and Nickel (Creatinine corrected) [mcg/g Creat; ICP/MS] were added. Order of reported analytes was changed.		
2663U	Metals/Metalloids Panel 3, Urine Scope of Analysis: Creatinine, Arsenic, Arsenic (Creatinine corrected), Lead, Lead (Creatinine corrected), Cadmium Cadmium (Creatinine corrected), Mercury, Mercury (Creatinine corrected), Chromium Chromium (Creatinine corrected) Arsenic (Creatinine correction), Lead (Creatinine correction), Cadmium (Creatinine correction) and Mercury (Creatinine correction) were removed. Arsenic (Creatinine corrected) [mcg/g Creat; ICP/MS], Lead (Creatinine corrected) [mcg/g Creat; ICP/MS], Cadmium (Creatinine correction) [mcg/g Creat; ICP/MS] and Mercury (Creatinine corrected) [mcg/g Creat; CVAAS] were added.		
3036U	Methyltin, Urine Scope of Analysis: Creatinine, Monomethyltin, Monomethyltin (Creatinine corrected), Dimethyltin, Dimethyltin (Creatinine corrected), Trimethyltin, Trimethyltin (Creatinine corrected) Monomethyltin (Creatinine correction), Dimethyltin (Creatinine correction), Tri-Methyltin and Tri-Methyltin (Creatinine correction) were removed. Monomethyltin (Creatinine corrected) [mcg/g Creat; GC], Dimethyltin (Creatinine corrected) [mcg/g Creat; GC], Trimethyltin [ng/mL; GC] and Trimethyltin (Creatinine corrected) [mcg/g Creat; GC] were added.		
3110B	Nalbuphine Screen - Free (Unconjugated), Blood Scope of Analysis: Nalbuphine - Free Nalbuphine was removed. Nalbuphine - Free [ng/mL; LC/MS/MS] was added. Test Name was changed.		

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
3110SP	Nalbuphine Screen - Free (Unconjugated), Serum/Plasma Scope of Analysis: Nalbuphine - Free Nalbuphine was removed. Nalbuphine - Free [ng/mL; LC/MS/MS] was added. Test Name was changed.		
3110U	Nalbuphine Screen - Total (Conjugated/Unconjugated), Urine Scope of Analysis: Nalbuphine - Total Nalbuphine was removed. Nalbuphine - Total [ng/mL; LC/MS/MS] was added. Test Name was changed.		
5118B	Nalbuphine Confirmation - Free (Unconjugated), Blood Scope of Analysis: Nalbuphine - Free Nalbuphine was removed. Nalbuphine - Free [ng/mL; LC/MS/MS] was added. Test Name was changed.		
5118SP	Nalbuphine Confirmation - Free (Unconjugated), Serum/Plasma Scope of Analysis: Nalbuphine - Free Nalbuphine was removed. Nalbuphine - Free [ng/mL; LC/MS/MS] was added. Test Name was changed.		
5118U	Nalbuphine Confirmation - Total (Conjugated/Unconjugated), Urine Scope of Analysis: Nalbuphine - Total Nalbuphine was removed. Nalbuphine - Total [ng/mL; LC/MS/MS] was added. Test Name was changed.		
3140U	Nickel, Urine Scope of Analysis: Creatinine, Nickel, Nickel (Creatinine corrected) Nickel (Creatinine correction) was removed. Nickel (Creatinine corrected) [mcg/g Creat; ICP/MS] was added.		
4240U	Sufentanil, Urine Scope of Analysis: Sufentanil, N-Desalkylsufentanil N-Desalkylsufentanil [ng/mL; LC/MS/MS] was added.		
5782U	Sufentanil Confirmation, Urine Scope of Analysis: Sufentanil, N-Desalkylsufentanil N-Desalkylsufentanil [ng/mL; LC/MS/MS] was added.		
4472U	Thiosulfate, Urine Scope of Analysis: Creatinine, Thiosulfate, Thiosulfate (Creatinine corrected) Thiosulfate (Creatinine correction) was removed. Thiosulfate (Creatinine corrected) [mcg/g Creat; IC] was added.		
4627U	Trichloroacetic Acid, Urine Scope of Analysis: Creatinine, Trichloroacetic Acid, Trichloroacetic Acid (Creatinine corrected) Trichloroacetic Acid (Creatinine correction) was removed. Trichloroacetic Acid (Creatinine corrected) [mg/g Creat; SP] was added. Order of reported analytes was changed.		

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code Changes	Unit Changes
4649U	Trichloroethylene Exposure Survey, Urine		
Scope of Analysis: Creatinine, Trichloroacetic Acid, Trichloroacetic Acid (Creatinine corrected), Trichloroethanol, Trichloroethanol (Creatinine corrected) Trichloroacetic Acid (Creatinine correction) and Trichloroethanol (Creatinine correction) were removed. Trichloroacetic Acid (Creatinine corrected) [mg/g Creat; SP] and Trichloroethanol (Creatinine corrected) [mg/g Creat; GC] were added. Order of reported analytes was changed.			
4778U	Vinyl Chloride Metabolite, Urine		
Scope of Analysis: Creatinine, Thiodyglycolic Acid, Thiodyglycolic Acid (Creatinine corrected) Thiodyglycolic Acid (Creatinine correction) was removed. Thiodyglycolic Acid (Creatinine corrected) [mg/g Creat; LC/MS/MS ; was added.			
4817U	Whitford Survey, Urine		
Scope of Analysis: Creatinine, Cadmium, Cadmium (Creatinine corrected), Chromium, Chromium (Creatinine corrected), Beta-2-Microglobulin, Beta-2-Microglobulin (Creatinine corrected) Cadmium (Creatinine correction) Chromium (Creatinine correction) and Beta-2-Microglobulin (Creatinine corrected) were removed. Cadmium (Creatinine corrected) [mcg/g Creat; ICP/MS], Chromium (Creatinine corrected) [mcg/g Creat; GFAAS] and Beta-2-Microglobulin (Creatinine corrected) [mcg/g Creat; EIA] were added. Order of reported analytes was changed.			
4821U	Xylene Exposure Panel, Urine		
Scope of Analysis: Creatinine, Methylhippuric Acid, Methylhippuric Acid (Creatinine corrected), Methylhippuric Acid (Creatinine correction) was removed. Methylhippuric Acid (Creatinine corrected) [g/g Creat; IC] was added.			

DISCONTINUED TESTS – CATEGORY II

Test Code	Test Name	Alternative Test
3778U	Plutonium, Urine	No alternate test available.
4082U	Radioisotope Panel, Urine	No alternate test available.
4084U	Radium, Urine	No alternate test available.
4551U	Tritium, Urine	No alternate test available.
8121B	Common Drugs of Abuse Screen, Blood (Forensic)	No alternate test available.
8121SP	Common Drugs of Abuse Screen, Serum/Plasma (Forensic)	No alternate test available.
8121U	Common Drugs of Abuse Screen, Urine (Forensic)	No alternate test available.
8676U	Opiates - Total (Conjugated and Unconjugated), Urine	8670U Opiates - Total (Conjugated/ Unconjugated), Urine

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name / Compound	New Reference Comment
8600U	Amphetamines Panel, Urine <ul style="list-style-type: none"> • Benzphetamine 	Benzphetamine is rapidly metabolized to Methamphetamine and Amphetamine.
5450B	Antidepressants Confirmation, Blood <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
5450SP	Antidepressants Confirmation, Serum/Plasma <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name / Compound	New Reference Comment
4655B	Antidepressants Panel 1, Blood <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
4655SP	Antidepressants Panel 1, Serum/Plasma <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
8700B	Antidepressants Panel, Blood <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name / Compound	New Reference Comment
8700SP	Antidepressants Panel, Serum/Plasma <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
5222B	Antidepressants Quantitation/Confirmation, Blood (Forensic) <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name / Compound	New Reference Comment
5222SP	Antidepressants Quantitation/Confirmation, Serum/Plasma (Forensic) <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
9431B	Antidepressants Screen, Blood <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
9431SP	Antidepressants Screen, Serum/Plasma <ul style="list-style-type: none"> • Doxepin • Desmethyldoxepin • Fluoxetine • Norfluoxetine 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name / Compound	New Reference Comment
5684U	Benzphetamine and Metabolite Confirmation, Urine <ul style="list-style-type: none"> Benzphetamine 	Benzphetamine is rapidly metabolized to Methamphetamine and Amphetamine.
0711B	Boron, Blood <ul style="list-style-type: none"> Boron 	Serum Boron levels do not correlate with severity of toxic symptoms; however, symptoms are generally observed at levels greater than 2000 mcg/dL.
0711SP	Boron, Serum/Plasma <ul style="list-style-type: none"> Boron 	Serum Boron levels do not correlate with severity of toxic symptoms; however, symptoms are generally observed at levels greater than 2000 mcg/dL.
1810B	Doxepin and Metabolite, Blood <ul style="list-style-type: none"> Doxepin Desmethyldoxepin 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p>
1810SP	Doxepin and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Doxepin Desmethyldoxepin 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p>
2105B	Fluoxetine and Metabolite, Blood <ul style="list-style-type: none"> Fluoxetine Norfluoxetine 	<p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
2105SP	Fluoxetine and Metabolite, Serum/Plasma <ul style="list-style-type: none"> Fluoxetine Norfluoxetine 	<p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>

Changes effective:
May 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name / Compound	New Reference Comment
2110B	Fluphenazine, Blood <ul style="list-style-type: none"> Fluphenazine 	<p>Steady-state antipsychotic levels following intramuscular decanoate ester dosing ever 1 to 2 weeks: 0.9 - 4.0 ng/mL at a dose of 12.5mg, 5 - 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg.</p> <p>Effective steady-state antipsychotic plasma levels with oral dosing: 0.1 - 3.0 ng/mL.</p>
2110SP	Fluphenazine, Serum/Plasma <ul style="list-style-type: none"> Fluphenazine 	<p>Steady-state antipsychotic levels following intramuscular decanoate ester dosing ever 1 to 2 weeks: 0.9 - 4.0 ng/mL at a dose of 12.5mg, 5 - 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg.</p> <p>Effective steady-state antipsychotic plasma levels with oral dosing: 0.1 - 3.0 ng/mL.</p>
2427B	Inhalants Survey (Comprehensive), Blood <ul style="list-style-type: none"> Hydrocarbon Gases 	<p>Note: Reporting Limit Range: 2 - 10 ppm (v/v).</p> <p>Scope of Analysis: Ethane, n-Butane, iso-Butane, Propane, Methane</p>
5118B	Nalbuphine Confirmation - Free (Unconjugated), Blood <ul style="list-style-type: none"> Nalbuphine 	<p>Peak plasma concentrations between 38 and 59 ng/mL were reported following a 10 mg IM dose.</p>
5118SP	Nalbuphine Confirmation - Free (Unconjugated), Serum/Plasma <ul style="list-style-type: none"> Nalbuphine 	<p>Peak plasma concentrations between 38 and 59 ng/mL were reported following a 10 mg IM dose.</p>
3110B	Nalbuphine Screen - Free (Unconjugated), Blood <ul style="list-style-type: none"> Nalbuphine 	<p>Peak plasma concentrations between 38 and 59 ng/mL were reported following a 10 mg IM dose.</p>
3110SP	Nalbuphine Screen - Free (Unconjugated), Serum/Plasma <ul style="list-style-type: none"> Nalbuphine 	<p>Peak plasma concentrations between 38 and 59 ng/mL were reported following a 10 mg IM dose.</p>

